
ŌURA Redefines Metabolic Health Tracking with Two New AI-Driven Features: Meals and Glucose
'Our product roadmap for this year is built on a robust investment in AI-forward offerings that enable a deeper understanding of the dynamic interplay of key health factors,' said Holly Shelton, chief product officer at ŌURA. 'The addition of nutrition-focused features to our product experience was a natural next step, especially considering how personal diet—and its impact on health—can be. Our bodies all process food in different ways, which is why we're leveraging a unique combination of ŌURA's extensive biometric tracking, generative AI, and Stelo glucose data to address a critical need for more individualized and accessible metabolic health solutions. By integrating nutrition information with activity, stress, and sleep, we're empowering members with a deeper understanding of how their daily habits influence their wellbeing.'
Metabolic health plays a critical role in overall vitality, affecting everything from energy levels and mood to long-term disease risk. While conditions such as Type 2 diabetes, hypertension, and obesity are on the rise—with over 800 million people globally living with obesity and nearly half a billion adults living with prediabetes—metabolic dysfunction can impact individuals even in the absence of a formal diagnosis. Poor metabolic health has been linked to increased risk of cardiovascular disease, stroke, kidney disease, and more, and may also contribute to everyday symptoms such as fatigue, brain fog, and decreased physical performance. As a result, supporting metabolic health is essential not only for managing disease but also for optimizing how individuals feel and function in daily life.
Proactive management through lifestyle changes can dramatically reduce these risks and symptoms; however, metabolic processes are intricate, and factors like genetics, hormones, and environmental influences can play a role. This complexity can make it difficult to pinpoint the most effective strategies for optimizing metabolic health.
Through its new Meals and Glucose features, in addition to its existing feature set spanning sleep, stress, activity, heart health, and more, ŌURA provides a comprehensive and integrated metabolic experience, setting it apart from existing offerings and directly responding to the growing demand for more personalized and holistic metabolic management tools.
Meals
After months of testing and supportive feedback in Oura Labs, Oura's innovation hub, Meals has transitioned to a permanent feature in the Oura App. By simply taking a picture, members can quickly log their food and see how effectively their meals and snacks fuel them through AI-powered food recognition and comprehensive nutrition analysis. Unlike traditional meal tracking apps that emphasize calorie counts, Meals focuses on macronutrients and is designed to help members better understand how their dietary choices affect their health, empowering them to develop sustainable habits aligned with their goals.
When members take or upload photos of their meals in the Oura App, ŌURA analyzes the dish to provide an immediate overview of its contents. Once analyzed, Oura Advisor provides guidance and feedback on nutritional choices so members can learn how to build satiating, nutrient-dense meals to avoid energy slumps and cravings.
Meals also includes a Nutrition Breakdown component, which categorizes key nutritional elements like protein, fiber, processing level, added sugars, total fats, and total carbs to provide an informational, at-a-glance summary. Oura's guidance avoids penalizing food choices, instead presenting non-judgmental insights that help members make informed choices based on their health objectives, whether that's improving energy levels, maintaining metabolic health, or enhancing dietary balance.
Glucose
Through ŌURA's strategic partnership and integration with Dexcom, a global leader in glucose biosensing, Oura members can now purchase a Stelo directly from ouraring.com to receive 24/7 glucose insights and gain a better understanding of their metabolic health. Stelo, a small biosensor worn on the back of the upper arm, leverages Dexcom's most accurate¹ glucose sensing technology and reveals how lifestyle factors can affect glucose.
Prior to Stelo's launch in August 2024, glucose biosensors were only available with a prescription, and often involved significant out-of-pocket costs for those without insurance coverage. Since receiving FDA-clearance, Stelo has expanded access to this technology, giving more people valuable information about their health. Members who integrate Stelo with Oura will see their daily glucose readings in the context of their meals, sleep, stress, and activity through a new Glucose feature in the Oura App.
'Personalized guidance and insights are essential for helping people understand how their lifestyle choices affect their body, while also encouraging them to make informed health decisions that can improve their overall quality of life,' said Jake Leach, executive vice president and chief operating officer at Dexcom. 'By integrating with ŌURA, we're bringing the first glucose biosensor and smart ring integration to the market, providing a one-of-a-kind and personalized metabolic health experience that allows users to better understand the link between activity, sleep, stress, nutrition, and their glucose. Through this partnership, we're once again redefining the wearable technology category in the pursuit of empowering people to take control of their health.'
Within the Glucose feature in the Oura App, contextual graphs and insights from Oura Advisor help members understand the interplay between meals, stress, daily movement, tags, and glucose so members can learn lifestyle habits that help them maintain or achieve optimal glucose levels. The feature will also provide a new key metric, 'Time Above Range,' which tracks how long glucose stays above the target range and provides an AI-powered analysis of glucose trends for that day.
'Our approach to metabolic health and glucose monitoring is uniquely ŌURA,' said Shyamal Patel, senior vice president of science at ŌURA. 'Meal-induced glucose spikes can vary significantly due to factors like sleep, stress, exercise, and meal timing, which is why it's important to approach metabolic health holistically rather than focusing exclusively on diet. Instead of avoiding specific foods based on one spike, we encourage members to observe patterns, experiment with habits, and discover what helps them maintain better glucose balance over time. With this approach, members can maintain a healthy relationship with food while building long-term habits that support metabolic health.'
AI-Powered Health Insights
Meals and Glucose join the suite of features supported by ŌURA's AI-powered health coach, Oura Advisor. Oura Advisor is a holistic LLM designed to give Oura members personalized, contextual, and empathetic guidance. In addition to integrating with various features in the Oura App, Oura Advisor can answer general health questions and pull in charts of a member's Sleep, Readiness, or Activity data to guide and support them in making changes that align with their health goals.
'AI has been part of the Oura experience since its inception, powering our core features and driving the personalized experience our members have come to know and love,' said Shelton. 'With the launch of Meals, Glucose, and Oura Advisor—and the strategic integration of AI across all three—we're taking a pivotal step forward in connecting the dots to deliver the most personal and holistic health platform available. This launch is a significant milestone in our goal to continuously innovate and give members agency over their health.'
Pricing and Availability
At launch, Meals and Glucose will be available on iOS and Android for Oura members based in the United States, with plans to launch Meals internationally later this year. Oura Advisor currently provides the most personalized responses about Oura data related to Sleep, Activity, Readiness, and Resilience. Oura Advisor intelligence will be released across additional Oura features in the coming months.
New and existing Oura members will be able to purchase Stelo directly from ouraring.com for $99. Each Stelo order includes two sensors for a wear-time of up to 15 days each. Stelo can be purchased bundled with or without a ring and will be available in the United States only.
Stelo is cleared by the FDA for adults not on insulin who are 18 or older * in the United States interested in tracking their glucose, and for people with Type 2 diabetes not using insulin or those with prediabetes. Both Oura Ring and Stelo are eligible for purchase with FSA/HSA funds.
To learn more about Oura's metabolic health features, visit here.
Stelo Safety Information: For full information on risks and benefits, visit stelo.com.
1 Dexcom, Data on File, 2024.
* Adults 18 years or older not on insulin.
About ŌURA:
ŌURA delivers personalized health data, insights, and daily guidance with Oura Ring, the leading smart ring that helps you live healthier, longer. Guided by a mission of changing the healthcare paradigm from sick care to preventative health, ŌURA makes wellness and recovery a daily practice through sleep, activity, readiness, stress, resilience, women's health, and heart health. Millions of Oura members around the world use Oura Ring as a personalized health companion that meets them where they are.
ŌURA is building the most scientifically validated wearable; the lightweight and comfortable Oura Ring is validated against medical gold standards and driven by continuous monitoring of 50+ individual health and wellness biometrics and insights. Thousands of teams, research organizations, and concierge medical practices manage the health of their populations with ŌURA, and its ecosystem includes 800+ partners across women's health, metabolic health, fitness, behavioral health, and more. ŌURA was founded in 2013 in Finland and has offices in Oulu, Helsinki, San Francisco, and San Diego. For more information, please visit http://ouraring.com/ and connect with ŌURA on Instagram, LinkedIn, and TikTok.
Oura Ring is not a medical device and is not intended to diagnose, treat, cure, monitor, or prevent medical conditions/illnesses.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
6 hours ago
- Associated Press
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS). This marks the second registrational Phase III study of lisaftoclax to receive clearance from both the FDA and EMA. The GLORA-4 study is simultaneously enrolling patients at participating centers in multiple countries, to accelerate the drug's path to potential market authorization. To date, lisaftoclax is the only Bcl-2 inhibitor being advanced in a registrational Phase III trial in higher-risk MDS globally. This study, if positive, may potentially end the longstanding treatment gap in higher-risk MDS, marking yet another major milestone in the global clinical development of lisaftoclax. Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, 'Globally, we still lack targeted therapies for first-line treatment of patients with higher-risk MDS, which represents a huge unmet clinical need. Currently, hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain the primary treatment options for higher-risk MDS. In earlier studies, lisaftoclax has demonstrated promising clinical benefit and tolerability. The clearances of the GLORA-4 study by the U.S. FDA and EMA, coinciding with the approval by the China CDE, pave the way for lisaftoclax to potentially become the first Bcl-2 inhibitor approved globally for first-line treatment of higher-risk MDS and the first targeted therapy approved for this indication since the introduction of HMA, which fundamentally reshapes the treatment landscape.' The GLORA-4 trial is being conducted simultaneously in China, the U.S., and Europe. This will significantly accelerate the clinical development of lisaftoclax in MDS and accelerate the drug's path to potential market authorization. Moving forward, we will remain steadfastly committed to our mission of addressing unmet clinical needs in China and around the world, actively advancing our clinical programs for the benefit of more patients.' GLORA-4 is a multi-region, multi-center, randomized, double-blind Phase III trial designed to evaluate the efficacy and safety of lisaftoclax in combination with AZA compared to placebo plus AZA in newly diagnosed adult patients with higher-risk MDS. The study was originally approved by the China CDE in 2024. Currently, the study is enrolling patients globally, with the first patients already enrolled in China and Europe. Guillermo Garcia-Manero, MD, Chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center (MDACC), and Prof. Xiaojun Huang, MD, an academician of the Chinese Academy of Engineering, director of the Institute of Hematology at Peking University, and director of the Department of Hematology at Peking University People's Hospital, are global co-leading principal investigators of the study. MDS is a myeloid clonal disease originating from hematopoietic stem cells with strongly age-correlated characteristics. Global epidemiological data of MDS show an exponential increase in incidence with age (22/100,000 in the population aged over 65 years), with a median age of diagnosis of 70 years1. More than 75% of patients with MDS present a complex disease profile that includes at least two comorbidities2. The primary risk of MDS is clonal evolution leading to progression to acute myeloid leukemia (AML), with 40-60% of higher-risk patients (high/very high risk, as classified by IPSS-R) progressing to AML within five years3. These patients have a dismal prognosis and a median survival of less than six months4. As the standard first-line therapy for higher-risk MDS, HMAs offer inadequate responses to treatment, with an overall response rate (ORR) of just 30-40%5, a complete response (CR) rate of 10-17%, and a median duration of response of 9-12 months6, 8. While allo-HSCT can offer a potential cure, it is limited by the median age of patients, complex disease profiles, common depletion of the hematopoietic stem cell reserve, and a transplantation-related mortality (TRM) rate of 25-35%. As a result, only 5-10% of eligible patients can receive transplantation7. The five-year survival rate of patients who are classified by the IPSS-R as high-risk remains at 16-24%8, highlighting an urgent unmet medical need for innovative therapies that can change the treatment paradigm. Lisaftoclax is a proprietary, novel, orally administered Bcl-2 selective inhibitor being developed by Ascentage Pharma to treat patients with malignancies by selectively blocking the anti-apoptotic protein Bcl-2 and restoring the normal apoptosis process in cancer cells. Lisaftoclax is already approved in China for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors. Previously, the Company released the clinical data of lisaftoclax in combination with AZA in treatment-naïve (TN) MDS during the 2024 American Society of Hematology (ASH) Annual Meeting and the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showed an ORR of 75%, much higher than HMAs alone, which demonstrated the clinical benefit of the combination regimen. The combination also showed a favorable safety profile, with a low incidence of severe hematologic toxicities and neutropenia-related infections. In addition, the proportion of patients requiring dose adjustments was low and there were no treatment-related mortalities within 60 days9, 10. Professor Huang commented, 'Despite the significant advancement in the treatment of hematologic malignancies, higher-risk MDS remains a major clinical challenge because of a range of factors. First, the current standard of care treatment with HMAs only offers limited efficacy, with just about one-third of patients achieving a response to treatment. Second, no breakthrough therapies have emerged globally in the two decades since the introduction of HMAs. As a result, there is an unmet clinical need for targeted therapies for higher-risk MDS. The compelling response rate and manageable safety profile observed in earlier studies of lisaftoclax are very encouraging. We hope this global Phase III study has the potential to provide new insights that could benefit how we treat and manage higher-risk MDS.' Dr. Garcia-Manero commented, 'Higher-risk MDS is more prevalent in older populations and thus presents unique clinical challenges. These patients often have multiple comorbidities and depleted hematopoietic reserves, making them less tolerant of treatment with particularly high requirement for safety. Preliminary clinical data of lisaftoclax demonstrated notable clinical benefit, with low rates of treatment-related dose adjustments and mortalities while maintaining significant response rates. We hope these characteristics of lisaftoclax will make it a potentially superior treatment option for patients.' References: About Ascentage Pharma Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST. The second lead asset, lisaftoclax, is the first China-approved third-generation Bcl-2 inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors. The Company is currently conducting 4 global registrational Phase III trials: the GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL who were previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed elderly and unfit patients with AML; and the GLORA-4 study in patients with newly diagnosed higher-risk MDS. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact Information Investor Relations: Hogan Wan, Head of IR and Strategy Ascentage Pharma [email protected] +86 512 85557777 Stephanie Carrington ICR Healthcare [email protected] +1 (646) 277-1282 Media Relations: Jon Yu ICR Healthcare [email protected] +1 (646) 677-1855
Yahoo
8 hours ago
- Yahoo
MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline
We recently published . MannKind Corporation (NASDAQ:MNKD) is one of the best healthcare stocks. MannKind Corporation (NASDAQ:MNKD)'s most recent milestone is its push to expand the use of its rapid-acting inhaled insulin, Afrezza, to pediatric patients. In August 2025, the company submitted a supplemental Biologics License Application to the FDA for use in children ages 4–17, supported by positive Phase 3 INHALE-1 trial results presented at major diabetes conferences. A regulatory decision is expected in Q4 2025. Clinical data from both pediatric (INHALE-1) and adult (INHALE-3) studies have reinforced Afrezza's efficacy and safety across age groups. These advances have also helped the business gain attention among investors looking at the best healthcare stocks. Beyond Afrezza, MannKind Corporation (NASDAQ:MNKD) is advancing its pipeline in respiratory and rare diseases. MNKD-101, an inhaled clofazimine for nontuberculous mycobacterial lung disease, is progressing ahead of schedule in its global Phase 3 ICoN-1 trial. MNKD-201, a therapy for idiopathic pulmonary fibrosis, is set to enter Phase 2 testing by the end of 2025. Copyright: nicoletaionescu / 123RF Stock Photo To support these initiatives, the business secured up to $500 million in non-dilutive financing from Blackstone in August 2025. This funding will accelerate the potential launch of pediatric Afrezza, expand its commercial capabilities, and advance its clinical programs. Together, these developments position MannKind Corporation (NASDAQ:MNKD) for growth in both diabetes care and specialty lung disease markets. While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
8 hours ago
- Yahoo
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates
We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best healthcare stocks. ImmunityBio, Inc. (NASDAQ:IBRX) is among the best healthcare stocks. It is a clinical-stage biotech company developing advanced immunotherapies and vaccines targeting cancers and infectious diseases by activating immune cells such as natural killer and T cells. A key recent milestone is the FDA-approved immunotherapy drug ANKTIVA for bladder cancer, specifically for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS). ANKTIVA, designated a Breakthrough Therapy, is expanding its clinical use, notably with the Michael E. DeBakey VA Medical Center in Houston becoming one of the first VA hospitals to administer the treatment to veterans, a population at higher bladder cancer risk. In Q2 2025, ImmunityBio, Inc. (NASDAQ:IBRX) reported a 60% revenue growth quarter-over-quarter, reaching $26.4 million and a year-to-date total of approximately $43 million. This growth is driven by increased commercial momentum post-approval and supported by an $80 million capital raise in July 2025 to fuel ongoing development and expansion. ImmunityBio, Inc. (NASDAQ:IBRX) is transitioning from a clinical-stage biotech to a commercial-stage company with ANKTIVA's expanding adoption, including recent UK regulatory approval for ANKTIVA plus BCG. The drug addresses an underserved cancer indication with the potential to reduce invasive treatments like cystectomy, backed by clinical data showing durable bladder preservation up to 36 months in responders. While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data